Drug Interaction Report

Acarbose has a major potential interaction with Cirrhosis.

The use of acarbose is contraindicated in patients with primary cirrhosis.

Acarbose has a major potential interaction with Colonic Ulceration.

The use of alpha-glucosidase inhibitors is contraindicated in patients with inflammatory bowel disease, colonic ulceration, partial intestinal obstruction, or any chronic intestinal disease associated with marked disorders of digestion or absorption. Alpha-glucosidase inhibitors competitively inhibit enzymes involved in the digestion of carbohydrates. Increased gas formation in the intestines due to fermentation of the undigested carbohydrates can worsen or aggravate intestinal problems.

Sirolimus protein-bound has a moderate potential interaction with Diabetes Mellitus.

Sirolimus albumin-bound can cause hyperglycemia. Fasting serum glucose should be monitored prior to starting treatment, and periodically during treatment in diabetic patients. Caution is advised.

Acarbose has a major potential interaction with Diabetic Ketoacidosis.

The use of alpha-glucosidase inhibitors is contraindicated for the treatment of patients with diabetic ketoacidosis.

Acarbose has a major potential interaction with Intestinal Obstruction.

The use of alpha-glucosidase inhibitors is contraindicated in patients with inflammatory bowel disease, colonic ulceration, partial intestinal obstruction, or any chronic intestinal disease associated with marked disorders of digestion or absorption. Alpha-glucosidase inhibitors competitively inhibit enzymes involved in the digestion of carbohydrates. Increased gas formation in the intestines due to fermentation of the undigested carbohydrates can worsen or aggravate intestinal problems.

Acarbose has a moderate potential interaction with Liver Disease.

The use of acarbose has been associated with dose-related elevations in serum transaminase levels and, rarely, hyperbilirubinemia and jaundice. Hepatic adverse effects may be more likely to occur at dosages exceeding 50 mg three times a day. Therapy with acarbose should be administered cautiously in patients with liver disease. Monitoring of serum transaminases is recommended every 3 months during the first year of treatment and periodically thereafter. If hepatotoxicity is suspected at any time, a dosage reduction or withdrawal of therapy may be indicated.

Sirolimus protein-bound has a moderate potential interaction with Liver Disease.

The use of sirolimus albumin-bound should be avoided in patients with severe hepatic impairment. Closely monitor patients with mild and moderate impairment for increased liver toxicity. Dosage should be reduced in these patients.

Acarbose has a major potential interaction with Malabsorption Syndrome.

The use of alpha-glucosidase inhibitors is contraindicated in patients with inflammatory bowel disease, colonic ulceration, partial intestinal obstruction, or any chronic intestinal disease associated with marked disorders of digestion or absorption. Alpha-glucosidase inhibitors competitively inhibit enzymes involved in the digestion of carbohydrates. Increased gas formation in the intestines due to fermentation of the undigested carbohydrates can worsen or aggravate intestinal problems.

Acarbose has a major potential interaction with Noninfectious Colitis.

The use of alpha-glucosidase inhibitors is contraindicated in patients with inflammatory bowel disease, colonic ulceration, partial intestinal obstruction, or any chronic intestinal disease associated with marked disorders of digestion or absorption. Alpha-glucosidase inhibitors competitively inhibit enzymes involved in the digestion of carbohydrates. Increased gas formation in the intestines due to fermentation of the undigested carbohydrates can worsen or aggravate intestinal problems.

Acarbose has a major potential interaction with Renal Dysfunction.

Acarbose may accumulate in patients with renal impairment. Following oral administration, 35% of a dose is recovered in the urine as either the parent drug or metabolites. However, long-term clinical trials in diabetic patients with significant renal dysfunction (serum creatinine > 2.0 mg/dL) have not been conducted. Therapy with acarbose should be administered cautiously in patients with renal dysfunction. The manufacturer does not recommend its use in patients with significantly impaired renal function.

Sirolimus protein-bound has a moderate potential interaction with Renal Dysfunction.

The effect of severe renal impairment on the pharmacokinetics of sirolimus albumin-bound is unknown. Caution and close monitoring is advised if using in these patients.

Sirolimus protein-bound has a moderate potential interaction with Vaccination.

Immunizations during treatment with sirolimus albumin-bound may be ineffective. Immunization with live vaccines is not recommended during treatment and close contact with those who have received live vaccines should be avoided. Required immunizations should be updated according to immunization guidelines prior to initiating treatment, if possible. The interval between live vaccinations and treatment initiation should be in accordance with current vaccination guidelines for patients on immunosuppressive therapies.